Versions Compared

Key

  • This line was added.
  • This line was removed.
  • Formatting was changed.

...

Page properties
Title

Psoriasis Area and Severity Index Version 2 Feldman (PASI V2FELDMAN)

CDISC ReferenceClinical Classification Supplement to the Study Data Tabulation Model Implementation Guide for Human Clinical Trials
QRS Short Name

PASI V2FELDMAN

QRS Permission StatusPublic Domain
TeamPsoriasis Standards Team and CDISC Questionnaires, Ratings, and Scales (QRS) Subteam
Supplement Version1.0
StatusDRAFT
Date2022-0307-1524
Notes
  • This supplement is intended to be used with other CDISC user guides for specific therapeutic/disease areas and follows the CDISC Study Data Tabulation Model Implementation Guide for Human Clinical Trials.

Revision History

...

© 2022 Clinical Data Interchange Standards Consortium, Inc. All rights reserved. 

1 Introduction

...

Known Issue(s)
  • Version 1 of the Psoriasis Area and Severity Index

...

  • CDISC Controlled Terminology (RSCAT=PASI with synonym=PASI01) is scheduled for deprecation and an associated

...

  • QRS supplement

...

  • will not be released.
  • There is

...

The representation of data collected for this instrument is based on the Study Data Tabulation Model Implementation Guide (SDTMIG) Disease Response and Clin Classification (RS) domain model, which can be found on the CDISC website at: https://www.cdisc.org/standards/foundational/sdtmig.

...

The CDISC Intellectual Property Policy can be found on the CDISC website at: https://www.cdisc.org/about/bylaws.

Info
titleReviewers input requested

CDISC would appreciate supplement reviewer’s input on their experience in using the Psoriasis Area and Severity Index instrument regarding what responses are being used for symptoms "erythema/redness", "thickness/induration" and "desquamation/scaling". There are 3 possible references that were found to explain PASI:

  • Feldman SR, Krueger GG. Psoriasis assessment tools in clinical trials. Ann Rheum Dis. 2005;64(Suppl 2):ii65–ii68.
    • Responses for symptoms are: none, slight, mild, moderate, severe.
  • Fredriksson T, Pettersson U. Severe psoriasis--oral therapy with a new retinoid. Dermatologica. 1978;157(4):238-44. doi: 10.1159/000250839. PMID: 357213.
    • Responses for symptoms are: none, slight, moderate, striking, exceptionally striking.
  • EMA guideline on Clinical Investigation of Medicinal Products Indicated for the Treatment of Psoriasis (https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-clinical-investigation-medicinal-products-indicated-treatment-psoriasis_en.pdf)
    • Responses for symptoms are based off Fredriksson (no symptoms, slight, moderate, marked, very marked) and are grouped as: mild to moderate, moderate, moderate to severe and severe. 

CDISC would appreciate reviewer help regarding which list of responses are used (those that mirror Feldman, Fredriksson, EMA or some other combination.

If the responses list is not in a majority (per public comment), it will be considered “undetermined”. The supplement will allow a sponsor’s list of responses, like the CDISC published in the PGI and CGI supplements.

1.1 Representations and Warranties, Limitations of Liability, and Disclaimers

This document is a supplement to the SDTMIG for Human Clinical Trials and is covered under Appendix F of that document, which describes representations, warranties, limitations of liability, and disclaimers. Please see Appendix F of the SDTMIG for a complete version of this material.

CDISC specifies how to structure the data that has been collected in a database, not what should be collected or how to conduct clinical assessments or protocols. CDISC disclaims any liability for your use of this material.

Although the United States Food and Drug Administration (US FDA) has provided input with regard to this supplement, this input does not constitute US FDA endorsement of any particular instrument.

2 Copyright Status

...

The CDISC documentation of this instrument consists of: (1) controlled terminology, (2) standard database structure with examples, and (3) CRF(s) annotated with the CDISC SDTMIG variables with submission values. 

Info
titleInformation for Reviewers

The CRF is attached at the top of the Wiki. When you click the paperclip image, you will find the file for the annotated CRF.

Note: CDISC Controlled Terminology is maintained by National Cancer Institute (NCI) Enterprise Vocabulary Services (EVS). The most recent version should be accessed through the CDISC website at: https://www.cdisc.org/standards/terminology/controlled-terminology.

Reference for the PASI V2:

Feldman SR, Krueger GG. Psoriasis assessment tools in clinical trials. Ann Rheum Dis. 2005;64(Suppl 2):ii65–ii68.

3 The RS Domain Model

3.1 Assumptions for the RS Domain Model

All assumptions and business rules described in the SDTMIG RS domain are applicable to this supplement. Additional assumptions specific to the PASI V2 are listed below.

The PASI V2 is a tool used to assess the severity of psoriasis. The PASI V2 breaks the body up into 4 sections (i.e., head, trunk, upper extremities, lower extremities) and assesses symptom severity and the percentage of each area affected by psoriasis. The symptoms are rated on a 5-point scale and the area is rated on a 7-point scale. Subscores for each section of the body and a total score are also captured.

...

The scale points for the symptoms include a numeric rating (0-4) and a definition of what is represented by the rating (e.g., 0 = "None"). For the PASI V2, RSORRES is populated with the text description while the numeric rating is represented in the standardized character and numeric result variables RSSTRESC and RSSTRESN.

  1. CDISC created a CRF based on the Feldman article using the symptom terms "erythema/redness", "thickness/induration" and "desquamation/scaling". As SMEs have recommended, we included desquamation with scaling even though desquamation is not referenced in the Feldman article.

...

The PASI V2 instrument includes subscores and a total score that are considered as captured data on the CRF and are not considered as derived in the example below. These scores may be submitted in SDTM or derived in the Analysis Data Model (ADaM) per scoring instructions from the Feldman reference.

  1. If operationally defined by the sponsor, it is the sponsor's responsibility to set the --DRVFL flag based on their eCRF process to derive subtotals and total scores. An investigator-derived score will be considered a captured score and not flagged. When subtotal and total scores are derived by the sponsor, the derived flag (--DRVFL) is set to "Y". However, when the subtotal and total scores are received from a central provider or vendor, the value would go into --ORRES and --DRVFL would be null (see SDTMIG Section 4.1.8.1, Origin Metadata for Variables).

  2. If scores are received by the sponsor, it is recommended that they are submitted to SDTM and verified in ADaM.

...

Records are created in rs.xpt for every item on the instrument

  1. For items with no data, RSORRES, RSSTRESC, and RSSTRESN are all missing and RSSTAT = "NOT DONE".  If the reason is known then that reason is represented in RSREASND (e.g., RSREASND = "REFUSED"). If the reason is unknown, then RSSTAT = "NOT DONE" and RSREASND is missing.

Terminology

...

RSCAT, RSTESTCD, and RSTEST values are included in CDISC Controlled Terminology.

...

3.2 Example for the PASI V2 RS Domain Model

The PASI V2 example below shows the terminology used to implement the instrument in the RS domain. This example shows the data for 1 subject collected at the baseline visit for the PASI V2 instrument. The example uses CDISC Controlled Terminology for RSTESTCD, RSTEST, and RSCAT. All original results, matching the CRF item response text, are represented in RSORRES. This result is then represented as a standard numeric score in RSSTRESN and as a standard character representation in RSSTRESC.

Jira
showSummaryfalse
serverIssue Tracker (JIRA)
serverId85506ce4-3cb3-3d91-85ee-f633aaaf4a45
keyQRSSUPP-329

Info

We are unable to make the example consistently show blue in the Wiki. All examples are updated for each QRS instrument so we ask that you please review the example below.

...

Namers

...

4 SDTM Mapping Strategy

This section is used for reference regarding the CRF data capture and to understand the alignment of the instrument to the SDTM RS domain. It also provides guidance on how the result variables (RSORRES, RSSTRESC, and RSSTRESN) should be populated.

RSTESTCD = "PASI0201" RSTEST = "PASI02-Head: Erythema/Redness"

RSTESTCD = "PASI0202" RSTEST = "PASI02-Head: Thickness/Induration"

RSTESTCD = "PASI0203" RSTEST = "PASI02-Head: Desquamation/Scaling"

RSTESTCD = "PASI0205" RSTEST = "PASI02-Up Extrem: Erythema/Redness"

RSTESTCD = "PASI0206" RSTEST = "PASI02-Up Extrem: Thickness/Induration"

RSTESTCD = "PASI0207" RSTEST = "PASI02-Up Extrem: Desquamation/Scaling"

RSTESTCD = "PASI0209" RSTEST = "PASI02-Trunk: Erythema/Redness"

RSTESTCD = "PASI0210" RSTEST = "PASI02-Trunk: Thickness/Induration"

RSTESTCD = "PASI0211" RSTEST = "PASI02-Trunk: Desquamation/Scaling"

RSTESTCD = "PASI0213" RSTEST = "PASI02-Low Extrem: Erythema/Redness"

RSTESTCD = "PASI0214" RSTEST = "PASI02-Low Extrem: Thickness/Induration"

RSTESTCD = "PASI0215" RSTEST = "PASI02-Low Extrem: Desquamation/Scaling"

...

RSTESTCD = "PASI0204" RSTEST = "PASI02-Head: Area Score"

RSTESTCD = "PASI0208" RSTEST = "PASI02-Up Extrem: Area Score"

RSTESTCD = "PASI0212" RSTEST = "PASI02-Trunk: Area Score"

RSTESTCD = "PASI0216" RSTEST = "PASI02-Low Extrem: Area Score"

...

End of Document

Info
titleInformation for Reviewers

Text in black is part of the template used to create this document and is not under review. Please review the blue text; this text represents the changes made to the template that are specific to this QRS instrument.

Page properties
This supplement is intended to be used with other CDISC user guides for specific therapeutic/disease areas and follows the CDISC Study Data Tabulation Model Implementation Guide for Human Clinical Trials
Title

Psoriasis Area and Severity Index Version 2 (PASI V2)

CDISC ReferenceClinical Classification Supplement to the Study Data Tabulation Model Implementation Guide for Human Clinical Trials
QRS Short Name

PASI V2

QRS Permission StatusPublic Domain
TeamPsoriasis Standards Team and CDISC Questionnaires, Ratings, and Scales (QRS) Subteam
Supplement Version1.0
StatusDRAFT
Date2021-07-28
Notes
  • not general agreement between industry, regulators, and academia on a standard set of responses for the PASI. Therefore, CDISC has created separate terminology and supplements for multiple references with different sets of responses for the PASI. This supplement uses the Feldman reference as the standard for responses.


Revision History

DateVersion
20212022-07-28241.0 Draft

© 2021 2022 Clinical Data Interchange Standards Consortium, Inc. All rights reserved. 

1 Introduction

This document describes the CDISC implementation of the Psoriasis Area and Severity Index Version 2 Feldman (PASI V2FELDMAN) instrument. Note that Version 1 of the CDISC Controlled Terminology is scheduled for deprecation and an associated CDISC Version 1 instrument and SDTMIG QRS supplement were never released.

...

These specific implementation details for this instrument are meant to be used in conjunction with the SDTMIG. All CDISC QuesionnairesQuestionnaires, Ratings and Scales (QRS)documentation packages can be found on the CDISC website at: https://www.cdisc.org/standards/foundational/qrs.

The CDISC Intellectual Property Policy can be found on the CDISC website at: https://www.cdisc.org/about/bylaws.

1.1 Representations and Warranties, Limitations of Liability, and Disclaimers

This document is a supplement to the SDTMIG for Human Clinical Trials and is covered under Appendix F of that document, which describes representations, warranties, limitations of liability, and disclaimers. Please see Appendix F of the SDTMIG for a complete version of this material.

...

Although the United States Food and Drug Administration (US FDA) has provided input with regard to this supplement, this input does not constitute US FDA endorsement of any particular instrument.

2 Copyright Status

CDISC believes this instrument to be in the public domain, but you should perform your own assessment. CDISC has included the PASI V2in the CDISC library of QRS data standards supplements. Hence, CDISC developed RSTESTCD and RSTEST for each item based on the actual text on the instrument. There may be many versions of this instrument. CDISC has chosen to use this version as the data standard.

...

Note: CDISC Controlled Terminology is maintained by National Cancer Institute (NCI) Enterprise Vocabulary Services (EVS). The most recent version should be accessed through the CDISC website at: https://www.cdisc.org/standards/terminology/controlled-terminology.

Reference for the PASI V2FELDMAN:

  • Feldman SR, Krueger GG. Psoriasis assessment tools in clinical trials.

...

  • Ann Rheum Dis. 2005;64(Suppl 2):

...

  • ii65–ii68.
  • CDISC believes this instrument to be in the public domain, but you should perform your own assessment.


3 The RS Domain Model

3.1 Assumptions for the RS Domain Model

All assumptions and business rules described in the SDTMIG RS domain are applicable to this supplement. Additional assumptions specific to the PASI V2 are FELDMAN are listed below.

The PASI V2FELDMAN is a tool used to assess the severity of psoriasis. The PASI V2 breaks the body up However, there is no standard set of responses for the PASI that is used throughout the industry. This supplement uses the Feldman article as the standard for responses. The PASI FELDMAN divides the body into 4 sections (i.e.,  headhead, trunk, upper extremities, lower extremities) and assesses symptom severity and the percentage of each area affected by psoriasis. The symptoms are rated on a 5-point scale and the area is rated on a 7-point scale. Subscores for each section of the body and a total score are also captured.

  1. The scale points for the symptoms include a numeric rating (0-4) and a definition of what is represented by the rating (e.g., 0 = "None"). For the PASI V2FELDMAN, RSORRES is populated with the text description while ; the numeric rating is represented in the standardized character and numeric result variables RSSTRESC and RSSTRESN.

    1. CDISC created a CRF based on the Feldman article using the symptom terms "erythema/redness," , "thickness/induration," and "desquamation/scaling". As SMEs have recommended, we included desquamation ." Per subject-matter expert recommendations, desquamation was included with scaling even though desquamation is not referenced in the Feldman article.
  2. The scale points for the area include a numeric rating (0-6) and a definition of what is represented by the rating (e.g., 0 = "No Involvement0 (clear)"). For the area, RSORRES is populated with the text description while ; the numeric rating is represented in the standardized character and numeric result variables RSSTRESC and RSSTRESN.
  3. The PASI V2 instrument FELDMAN instrument includes subscores and a total score that are considered as captured data on the CRF and are not considered as derived in the example below. These scores may be submitted in SDTM or derived in the Analysis Data Model (ADaM) per scoring instructions from the Feldman reference.

    1. If operationally defined by the sponsor, it is the sponsor's responsibility to set the --DRVFL flag based on their eCRF process to derive subtotals and total scores. An investigator-derived score will be considered a captured score and not flagged. When subtotal and total scores are derived by the sponsor, the derived flag (--DRVFL) is set to "Y". However, when the subtotal and total scores are received from a central provider or vendor, the value would go into --ORRES and --DRVFL would be null (see SDTMIG Section 4.1.8.1, Origin Metadata for Variables).

    2. If scores are received by the sponsor, it is recommended that they are submitted to SDTM and verified in ADaM.

  4. Records are created in rs.xpt for every item on the instrument

    1. For items with no data, RSORRES, RSSTRESC, and RSSTRESN are all missing and RSSTAT = "NOT DONE".  If the reason is known then , that reason is represented in RSREASND (e.g., RSREASND = "REFUSED"). If the reason is unknown, then RSSTAT = "NOT DONE" and RSREASND is missing.

  5. Terminology

    1. RSCAT, RSTESTCD, and RSTEST values are included in CDISC Controlled Terminology.

    2. A full list of value sets for the result field is provided in Section 4, SDTM Mapping Strategy.

3.2 Example for the PASI

...

FELDMAN RS Domain Model

The PASI V2 FELDMAN example below shows the terminology used to implement the instrument in the RS domain. This example shows the data for 1 subject collected at the baseline visit for the PASI V2 instrument. The example uses CDISC Controlled Terminology for RSTESTCD, RSTEST, and RSCAT. All original results, matching the CRF item response text, are represented with preferred terminology in RSORRES. This result is then transformed into the represented as a standard numeric score in RSSTRESN and as a standard character representation of the standard numeric score in RSSTRESC.


Info

We are unable to make the example consistently show blue in the Wiki. All examples are updated for each QRS instrument so we ask that you please review the example below.


The table represents the items from the PASI V2 instrumentFELDMAN instrument.

Dataset wrap
Namers
Rowcaps
Rows 1-16:Show the symptom and area responses for the baseline visit.
Rows 17-29:Show the subscores and total scores for the baseline visit.
Rows 30-59:Show the subject was not evaluated on this instrument at visit 2. Since the reason for not completing the visit was collected, the date is included in RSDTC for when the visit was planned.
Dataset2
RowSTUDYIDDOMAINUSUBJIDRSSEQRSTESTCDRSTESTRSCATRSORRESRSSTRESCRSSTRESNRSSTATRSREASNDRSLOBXFLVISITNUMRSDTC
1STUDYXRS2324-P00011PASI0201PASI02-Head: Erythema/Redness
PASI V2FELDMANSlight11

Y12015-05-15
2STUDYXRS2324-P00012PASI0202PASI02-Head: Thickness/Induration
PASI V2FELDMANNone00

Y12015-05-15
3STUDYXRS2324-P00013PASI0203PASI02-Head: Desquamation/Scaling
PASI V2FELDMANNone00

Y12015-05-15
4STUDYXRS2324-P00014PASI0204PASI02-Head: Area Score
PASI V2FELDMAN1% - 9%<10%11

Y12015-05-15
5STUDYXRS2324-P00015PASI0205PASI02-Up Extrem: Erythema/Redness
PASI V2FELDMANMild22

Y12015-05-15
6STUDYXRS2324-P00016PASI0206PASI02-Up Extrem: Thickness/Induration
PASI V2FELDMANSlight11

Y12015-05-15
7STUDYXRS2324-P00017PASI0207PASI02-Up Extrem: Desquamation/Scaling
PASI V2FELDMANMild22

Y12015-05-15
8STUDYXRS2324-P00018PASI0208PASI02-Up Extrem: Area Score
PASI V2FELDMAN30% 30 - 49%<50%33

Y12015-05-15
9STUDYXRS2324-P00019PASI0209PASI02-Trunk: Erythema/Redness
PASI V2FELDMANNone00

Y12015-05-15
10STUDYXRS2324-P000110PASI0210PASI02-Trunk: Thickness/Induration
PASI V2FELDMANNone00

Y12015-05-15
11STUDYXRS2324-P000111PASI0211PASI02-Trunk: Desquamation/Scaling
PASI V2FELDMANNone00

Y12015-05-15
12STUDYXRS2324-P000112PASI0212PASI02-Trunk: Area Score
PASI V2FELDMAN0 (clear)No Involvment00

Y12015-05-15
13STUDYXRS2324-P000113PASI0213PASI02-Low Extrem: Erythema/Redness
PASI V2FELDMANSlight11

Y12015-05-15
14STUDYXRS2324-P000114PASI0214PASI02-Low Extrem: Thickness/Induration
PASI V2FELDMANSlight11

Y12015-05-15
15STUDYXRS2324-P000115PASI0215PASI02-Low Extrem: Desquamation/Scaling
PASI V2FELDMANSlight11

Y12015-05-15
16STUDYXRS2324-P000116PASI0216PASI02-Low Extrem: Area Score
PASI V2FELDMAN10% 10 - 29%<30%1212

Y12015-05-15
17STUDYXRS2324-P000117PASI0217PASI02-Head: Sum of Symptom Scores
PASI V2FELDMAN111

Y12015-05-15
18STUDYXRS2324-P000118PASI0218PASI02-Head: Sum X Area
PASI V2FELDMAN111

Y12015-05-15
19STUDYXRS2324-P000119PASI0219PASI02-Head: Sum X Area X 0.1
PASI V2FELDMAN0.10.10.1

Y12015-05-15
20STUDYXRS2324-P000120PASI0220PASI02-Up Extrem: Sum of Symptom Scores
PASI V2FELDMAN555

Y12015-05-15
21STUDYXRS2324-P000121PASI0221PASI02-Up Extrem: Sum X Area
PASI V2FELDMAN151515

Y12015-05-15
22STUDYXRS2324-P000122PASI0222PASI02-Up Extrem: Sum X Area X 0.2
PASI V2FELDMAN333

Y12015-05-15
23STUDYXRS2324-P000123PASI0223PASI02-Trunk: Sum of Symptom Scores
PASI V2FELDMAN000

Y12015-05-15
24STUDYXRS2324-P000124PASI0224PASI02-Trunk: Sum X Area
PASI V2FELDMAN000

Y12015-05-15
25STUDYXRS2324-P000125PASI0225PASI02-Trunk: Sum X Area X 0.3
PASI V2FELDMAN000

Y12015-05-15
26STUDYXRS2324-P000126PASI0226PASI02-Low Extrem: Sum of Symptom Scores
PASI V2FELDMAN333

Y12015-05-15
27STUDYXRS2324-P000127PASI0227PASI02-Low Extrem: Sum X Area
PASI V2FELDMAN363636

Y12015-05-15
28STUDYXRS2324-P000128PASI0228PASI02-Low Extrem: Sum X Area X 0.4
PASI V2FELDMAN12.42.41.21.24

Y12015-05-15
29STUDYXRS2324-P000129PASI0229PASI02-Total Sum
PASI V2FELDMAN45.3545.3545.35

Y12015-05-15
30STUDYXRS2324-P000130PASI0201PASI02-Head: Erythema/Redness
PASI V2FELDMAN


NOT DONEREFUSED
22015-06-14
31STUDYXRS2324-P000131PASI0202PASI02-Head: Thickness/Induration
PASI V2FELDMAN


NOT DONEREFUSED
22015-06-14
32STUDYXRS2324-P000132PASI0203PASI02-Head: Desquamation/Scaling
PASI V2FELDMAN


NOT DONEREFUSED
22015-06-14
...














59STUDYXRS2324-P000159PASI0229PASI02-Total Sum
PASI V2FELDMAN


NOT DONEREFUSED
22015-06-14


4 SDTM Mapping Strategy

This section is used for reference regarding the CRF data capture and to understand the alignment of the instrument to the SDTM RS domain. It also provides guidance on how the result variables (RSORRES, RSSTRESC, and RSSTRESN) should be populated.

...

RSTESTCD = "PASI0216" RSTEST = "PASI02-Low Extrem: Area Score"

RSORRESRSSTRESCRSSTRESN
No Involvement0 (clear)00
1% - 9%<10%11
10% - 29%<30%22
30% - 49%<50%33
50% - 69%<70%44
70% - 89%<90%55
90% - 100%66


End of Document